- Pharma & healthcare
International pharmaceutical group
Climate risk analysis for 15 own and 20 supplier sites, with a particular focus on the supply and cold chain.
View detailsHide details
- Challenge
- Physical and transition climate risk analysis under IFRS/TCFD, including a focus on the supply and cold chain.
- Approach
- Site scoping, qualitative analysis along the supply chain, production and sales markets, quantitative scenario analysis (2.5 °C/4 °C physical, 1.5 °C/2.5 °C transition), board workshop.
- Result
- Financial impacts up to 2050/2100 per scenario, separate analysis of the main suppliers and transport routes.